Citation Impact
Citing Papers
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Topological control of cytokine receptor signaling induces differential effects in hematopoiesis
2019 StandoutScienceNobel
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
2004 Science
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer
2007
Triple-Negative Breast Cancer
2010 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Southwestern Internal Medicine Conference: Clinical Use of Hematopoietic Growth Factors
1993
A view on drug resistance in cancer
2019 StandoutNature
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
1990 StandoutNature
Comparing antibody and small-molecule therapies for cancer
2006
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Molecular mechanisms of drug resistance
2005
Metronomic therapy for breast cancer
2004
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
The generation of diversity and pattern in animal development
1992 StandoutNobel
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells
1989 StandoutNature
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
1991 StandoutNature
Individual patient data analysis to assess modifications to the RECIST criteria
2008
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
How basal are triple‐negative breast cancers?
2008
Chemotherapy and the war on cancer
2005 Standout
Angiogenesis in life, disease and medicine
2005 StandoutNature
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
2005
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
2007
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
2007
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
2004 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Where next for gefitinib in patients with lung cancer?
2006
Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis
1990 Nature
EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non–small Cell Lung Cancer
2006
Strategies for optimizing combinations of molecularly targeted anticancer agents
2006
The colony-stimulating factors and cancer
2010
Neutrophils in cancer: neutral no more
2016 Standout
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Predicting the outcome of chemotherapy for lung cancer
2006
Antimicrobial peptides of multicellular organisms
2002 StandoutNature
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
1997 StandoutNature
Gefitinib for non-small-cell lung cancer treatment
2011
Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium
1990
Liver damage in patients with colony-stimulating factor-producing tumors
1993 StandoutNobel
Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
2001
Angiogenesis as a therapeutic target
2005 StandoutNature
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Anemia of Chronic Disease
2005 Standout
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
The cancer genome
2009 StandoutNature
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor
1992
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
2006
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
2007
Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development
2007
Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.
1992 StandoutNobel
Tissue Engineering
1993 StandoutScience
Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer
2004
Beta-lactam antibiotics potentiate magainin 2 antimicrobial activity in vitro and in vivo
1991
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo.
1991
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
2005
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
2006
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
2005
Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations
2006
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
2005
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
2007
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
2009
Hematopoietic cytokines
2008
Dose escalation study of recombinant human granulocyte-colony-stimulating factor (KRN8601) in patients with advanced malignancy.
1989
Growth Factors and Cancer
1991 StandoutScience
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers
2005
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
G 1 Events and Regulation of Cell Proliferation
1989 StandoutScience
Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924
2001
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
2009
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
2007
Expression cloning of a human granulocyte colony-stimulating factor receptor: a structural mosaic of hematopoietin receptor, immunoglobulin, and fibronectin domains.
1990
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
2007
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Cytokine-induced radiation protection and sensitization
1996
Works of John Grous being referenced
Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
1988
Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.
1988
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
1991 Standout
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
2004
Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP)
2004
Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP)
2004
Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy
2004
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
2004